deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT01310803

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER

Sponsor: Endo Pharmaceuticals

Conditions Carcinoma in Situ Non-muscle Invasive Bladder Cancer Transitional Cell Carcinoma
Interventions No Maintenance treatment ( Standard of Care) VALSTAR - Maintenance Therapy
Updated 8 times since 2017 Last updated: Sep 7, 2017 Started: May 31, 2011 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Endo Pharmaceuticals

See all terminations from Endo Pharmaceuticals

A PHASE3 clinical study on Carcinoma in Situ and Non-muscle Invasive Bladder Cancer, this trial is terminated or withdrawn. The trial is conducted by Endo Pharmaceuticals and has accumulated 8 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshotTerminated~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 3 earlier versions

  1. Oct 2017 — Jun 2018 [monthly]

    Terminated PHASE3

  2. Feb 2017 — Oct 2017 [monthly]

    Terminated PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Endo Pharmaceuticals
Data source: Endo Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations